Fly News Breaks for March 28, 2017
REGN
Mar 28, 2017 | 12:40 EDT
Piper Jaffray analyst Edward Tenthoff believes the just approved Dupixent's label is favorable from a safety perspective and consistent with the patient population. The analyst sees further opportunity for the drug in children with atopic dermatitis and reiterates an Overweight rating on Regeneron shares with a $446 price target.
News For REGN From the Last 2 Days